Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of immunotherapy in advanced melanoma in relation to age.
Authors
Krishna Prasad Joshi
University of Arkansas for Medical Sciences, Little Rock, AR
Krishna Prasad Joshi, Dinesh Atwal, Rahul Ravilla, Jun Tao, Joseph Su, Issam Makhoul, Laura Fulper Hutchins, Fade A. Mahmoud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 187)
DOI
10.1200/JCO.2018.36.5_suppl.187
Abstract #
187
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.
First Author: Simon B. Zeichner
Poster
2021 ASCO Annual Meeting
Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.
First Author: Vincent T Ma
Poster
2020 ASCO Virtual Scientific Program
FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
First Author: Amir Iravani
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO).
First Author: Tamara A. Sussman